$57.49
1.492.66%
Last update: Oct 29, 5:15 PM
BioMarin Pharmaceutical Inc
BMRNNASDAQ
BioMarin Pharmaceutical (BMRN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BioMarin Pharmaceutical (BMRN) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided earnings per share in the range of $4.9 - $5.1, compared to a consensus EPS estimate of $4.8. BioMarin Pharmaceutical also guided revenue in the range of $3.88B - $3.92B for the period.
Compared to prior guidance, BioMarin Pharmaceutical raised its EPS outlook from a previous range of $4.85 - $5.05. On the revenue side, the company maintained its revenue forecast from a prior range of $3.83B - $3.92B.
BioMarin Pharmaceutical has issued 19 guidance updates between February 27, 2023 and August 6, 2026. During this period, the company raised its outlook 10 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.92 | $0.89 | $0.36 | $0.51 |
| Actual | $1.20 | $0.76 | $0.46 | $0.12 |
| Surprise | +30.4% | -14.6% | +27.8% | -76.5% |
| Revenue | ||||
| Estimate | $931.3M | $754.6M | $832.9M | $781.9M |
| Actual | $990.0M | $766.2M | $875.0M | $776.1M |
| Surprise | +6.30% | +1.54% | +5.06% | -0.74% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.15 | $1.62 | $1.24 | $1.36 |
| Revenue | ||||
| Consensus | $1.02B | $1.14B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.20 | $0.92 | 30.4 % |
| Q1 | May 4, 2026 | $0.76 | $0.89 | -14.6 % |
| Q4 | Feb 23, 2026 | $0.46 | $0.36 | 27.8 % |
| Q3 | Oct 27, 2025 | $0.12 | $0.51 | -76.5 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $990.00M | $931.29M | 6.30 % |
| Q1 | May 4, 2026 | $766.21M | $754.59M | 1.54 % |
| Q4 | Feb 23, 2026 | $875.00M | $832.88M | 5.06 % |
| Q3 | Oct 27, 2025 | $776.13M | $781.89M | -0.74 % |
